{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-049821","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.047621+00:00","generated_at":"2026-05-16T23:44:49.666639+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BeOne Medicines Q3 2025: total revenue up 41% to $1.4B, GAAP EPS $1.09","bullets":["Total revenue $1.41B, +41% YoY; BRUKINSA revenue $1.0B, +51% YoY.","GAAP diluted EPS $1.09; non-GAAP diluted EPS $2.65, up from $0.48 a year ago.","GAAP net income $124.8M vs loss $121.4M in Q3 2024; adjusted net income $303.7M.","47 abstracts accepted at ASH 2025; pipeline advances with sonrotoclax (BCL2 inhibitor) and BTK CDAC BGB-16673.","Free cash flow $354.5M, up 548% from $54.7M in Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-049821","json":"https://secwatch.observer/filing/0001628280-25-049821.json","markdown":"https://secwatch.observer/filing/0001628280-25-049821.md","text":"https://secwatch.observer/filing/0001628280-25-049821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000162828025049821/0001628280-25-049821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000162828025049821/bgne-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:44:49.666639+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}